Welcome to our dedicated page for Palvella Therapeutics SEC filings (Ticker: PVLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Palvella Therapeutics, Inc. (Nasdaq: PVLA) SEC filings page on Stock Titan provides access to the company’s official disclosures as a clinical-stage biopharmaceutical issuer. Palvella’s filings describe a business focused on developing investigational topical therapies for serious, rare skin diseases and vascular malformations with no FDA-approved therapies, built around its patented QTORIN™ platform.
Through documents such as Form 8-K current reports, investors can review how Palvella communicates material events, including topline results from the Phase 2 TOIVA trial of QTORIN™ rapamycin for cutaneous venous malformations, updates on the Phase 3 SELVA trial in microcystic lymphatic malformations, and announcements of new product candidates like QTORIN™ pitavastatin for disseminated superficial actinic porokeratosis. Other 8-K filings furnish earnings press releases, corporate presentations, and information about conference calls related to quarterly financial results and corporate updates.
These filings also confirm key structural details, such as Palvella’s incorporation in Nevada, its listing of common stock on The Nasdaq Capital Market under the symbol PVLA, and its description as a clinical-stage company. Regulation FD disclosures provide slide decks and presentations that elaborate on the company’s pipeline, regulatory designations, and development plans, while results-of-operations filings supply context on research and development spending and general and administrative costs associated with advancing QTORIN™ programs.
On Stock Titan, users can combine real-time updates from EDGAR with AI-assisted views of Palvella’s filings to more quickly understand the significance of new 8-Ks and related exhibits. This includes identifying which filings discuss clinical data, regulatory interactions, or financial performance, and how those disclosures relate to the company’s investigational product candidates, all while recognizing that QTORIN™ rapamycin and QTORIN™ pitavastatin remain unapproved therapies.
Palvella Therapeutics, Inc. disclosed that its Chief Scientific Officer, Jeffrey S. Martini, received a stock option grant. On February 5, 2026, he was awarded options to purchase 64,318 shares of common stock at an exercise price of $76.43 per share, granted for no cash cost.
The option vests in equal monthly installments over 48 months, beginning February 5, 2026, and each vesting installment requires his continuous service through the applicable vesting date.
Palvella Therapeutics, Inc. granted its Chief Commercial Officer, Ashley Hartmann, a stock option for 38,517 shares of common stock on February 5, 2026. The option has an exercise price of $76.43 per share and expires on February 5, 2036.
The option vests in equal monthly installments over 48 months, starting February 5, 2026, and remains subject to Hartmann’s continuous service with the company through each vesting date. All 38,517 derivative securities are reported as directly owned following this grant.
Palvella Therapeutics President and CEO Wes Kaupinen received a grant of 124,603 stock options on February 5, 2026. The options have an exercise price of $76.43 per share and are held directly.
The award vests in equal monthly installments over 48 months starting February 5, 2026, contingent on his continued service. Following this grant, Kaupinen beneficially owns 124,603 derivative securities tied to Palvella Therapeutics common stock.
Palvella Therapeutics, Inc. reported that CFO and Treasurer Matthew E. Korenberg received a grant of stock options for 44,123 shares of common stock on February 5, 2026. The options carry an exercise price of $76.43 per share and expire on February 5, 2036.
The options vest in equal monthly installments over 48 months starting February 5, 2026, as long as he remains in continuous service through each vesting date. Following this award, he beneficially holds 44,123 derivative securities directly.
Palvella Therapeutics Chief Operating Officer Kathleen Goin reported receiving a stock option grant. On February 5, 2026, she was awarded options to purchase 48,956 shares of common stock at an exercise price of $76.43 per share, expiring February 5, 2036.
The options vest in equal monthly installments over 48 months starting February 5, 2026, and each vesting date requires her continued service. All 48,956 derivative securities are held directly following this grant.
Palvella Therapeutics, Inc. filed a current report to note that it has posted a new corporate presentation on its website. The presentation, dated January 29, 2026 and filed as Exhibit 99.1, will be used by company representatives in various investor meetings.
The filing does not introduce new financial results or major transactions, but formally makes the investor presentation part of the public record by incorporating it by reference into the report.
Palvella Therapeutics Chief Operating Officer Kathleen Goin reported option exercises and related share sales in Palvella Therapeutics, Inc. common stock. On January 21, 2026, she exercised stock options for 2,154 shares at $7.14 and 2,148 shares at $9.08 per share. The resulting common shares were then sold in two transactions totaling 4,302 shares, with 553 shares sold at $95.49 and 3,749 shares sold at $97.94, leaving no directly held common stock reported after these sales. Following the option exercises, she continued to hold 19,397 and 19,332 stock options, each fully vested. The filing states that all transactions were carried out under a Rule 10b5‑1 trading plan adopted on August 19, 2025 during an open trading window and approved under the company’s insider trading policy.
Palvella Therapeutics insider plans another Rule 144 stock sale. A person filing through Piper Sandler & Co. intends to sell 4,302 shares of Palvella Therapeutics common stock on or about 01/21/2026 on the Nasdaq market, with an aggregate market value of 421,639.02 reported for this planned sale. The shares are being acquired the same day via a stock option exercise from the issuer, paid in cash, and then sold.
The filing also notes that the same seller, identified as Kathleen Goin c/o Palvella Therapeutics, previously sold 4,302 shares of common stock on 11/19/2025 for gross proceeds of 370,750.23 and another 4,302 shares on 12/17/2025 for gross proceeds of 415,022.54. The notice includes a representation that the seller is not aware of any undisclosed material adverse information about Palvella Therapeutics’ current or prospective operations.
Palvella Therapeutics, Inc. filed a current report to note that on January 12, 2026 it posted a new corporate presentation on its website. Company representatives plan to use this presentation in meetings with investors from time to time. The presentation is also included as Exhibit 99.1 to the report, making the same information available through the SEC’s system.